Glytec LLC Named Fierce Innovation Awards Finalist, Healthcare Edition, for Precision Diabetes Management Solution

The awards competition shines a light on the company’s patented eGlycemic Management System®, or eGMS®.

WALTHAM, Mass.--(BUSINESS WIRE)--FierceMarkets, the publisher of FierceHealthcare, FierceHealthIT and FierceHealthPayer, has named Glytec a finalist in the 2016 annual Healthcare Edition of its Fierce Innovation Awards program.

“Working with health systems to produce the best possible clinical and financial outcomes is what Glytec is all about”

One of the primary goals of the program is, ‘To identify and reward the fiercest, most evolutionary technologies and services that can transform healthcare delivery and operational success.’

Glytec’s eGlycemic Management System, or eGMS®, was evaluated and scored by a judging panel on the merits of multiple criteria, including care efficiency, competitive advantage, financial impact/value, market need, patient experience/satisfaction, quality of care and patient outcomes, and overall fierceness and innovation. The company is a finalist in the Clinical Information Management category.

The judging panel includes CIOs and clinical leaders from some of the nation’s top healthcare systems, medical practices and ACOs, including Aspirus, Cook Children’s Health Care System, JFK Health System, Tufts Health Plan, Independence Blue Cross, and others.

“We are very pleased that such a distinguished panel thoroughly evaluated our eGMS® and selected us as a finalist. Our thanks to Fierce for providing an important service and raising awareness of emerging, impactful technologies,” says Glytec’s CEO, Bob Leonard. “Glytec’s success in helping providers reduce the risks, challenges and costs surrounding insulin dosing and glycemic management is well documented, but the magnitude of the problem is not well understood in some circles. The inadequacies and dangers of traditional approaches to insulin management can adversely affect 40% of hospitalized patients, while 50% of those on insulin therapy outside of the hospital are not at their A1c goal. The associated costs to the U.S. healthcare system are staggering. On the inpatient front, our eGMS® is delivering an annualized savings as high as $10,000 per licensed bed, while on the outpatient front, reductions in patients’ A1c levels carry significant, well-quantified savings opportunities.”

Poor glucose control, due to inadequate or imprecise insulin dosing, leads to increased risk of complications, adverse drug events and mortality; longer lengths of stay; higher readmission rates; and avoidable ED visits and hospitalizations. The company’s eGMS® centers on prescription software, specifically, proprietary complex insulin dosing algorithms, while also offering an array of complementary decision support tools. The system was developed with significant input from end-user providers over the company’s now 10-year history. Contrary to traditional, static approaches to insulin management, the eGMS® calculates individualized doses to match the unique insulin sensitivities of each patient treated, and dynamically adjusts them over time.

“Working with health systems to produce the best possible clinical and financial outcomes is what Glytec is all about,” says the company’s Chief Medical Officer, Andrew S. Rhinehart, MD, FACP, FACE, CDE, BC-ADM, CDTC. “Our focus is on optimizing diabetes care across the continuum, whether patients are hospitalized or at home. This is especially important as the majority of health systems transition to risk- and value-based payment programs. It’s great to see that Fierce is helping expand awareness of the fact there’s a solution available to a problem that’s been plaguing providers and patients for decades.”

About Glytec

As a leading innovator in the care of patients with diabetes, Glytec is pioneering the way hospitals and health systems use technology to ensure optimal glucose control and reduce the frequency, risks and costs of hyperglycemia and hypoglycemia. The company, founded in 2006, has developed a comprehensive eGlycemic Management System®, or eGMS®, which centers on the only FDA-cleared solution for insulin dosing able to support personalized intravenous and subcutaneous therapy for adult and pediatric populations across the entire care continuum. The solution seamlessly integrates with EMR systems for streamlined use in all inpatient and outpatient settings. It also integrates with connected devices for at-home care managed through telehealth, population health and other value-based programs. The eGMS® employs a cloud-hosted software-as-a-service (SaaS) delivery model, allowing for rapid implementation and anytime/anywhere access. The efficacy of the eGMS®, including its ability to substantively improve clinical and financial outcomes, has been validated by more than 55 published studies. Results have included dramatic reductions in lengths of stay, readmissions and A1c levels. Glytec currently holds five U.S. patents and has an additional 32 U.S. and international patents pending. The company has offices in Waltham, Massachusetts, and Greenville, South Carolina. For more information, visit www.glytecsystems.com.

About FierceMarkets

FierceMarkets, a division of Questex, LLC, is a leader in B2B e-media, providing information and marketing services in the telecommunications, life sciences, healthcare and technology industries through its portfolio of email newsletters, websites, webinars and live events. Every business day, FierceMarkets' wide array of digital publications reaches more than 2 million executives in more than 100 countries.

Current publications include: Telecom: FierceWireless; FierceCable; FierceDeveloper; FierceOnlineVideo; FierceTelecom; FierceWirelessTech; FierceWireless:Europe/TelecomsEMEA, FierceInstaller; Healthcare: FierceEMR; FierceHealthcare; FierceHealthFinance; FierceHealthIT; FierceHealthPayer; FierceHealthPayerAntiFraud; FierceMobileHealthcare; FiercePracticeManagement and Hospital Impact; Life Sciences: FierceAnimalHealth; FierceBiotech; FierceBiotechIT; FierceBiotechResearch; FierceCRO; FierceDiagnostics, FierceDrugDelivery; FierceMedicalDevices; FiercePharma; FiercePharmaAsia; FiercePharmaMarketing; FiercePharmaManufacturing; and FierceVaccines; Technology: FierceTechExec.